Piper Jaffray Downgrades Intra-Cellular Therapies (ITCI) to Neutral

May 1, 2017 10:57 AM EDT
Get Alerts ITCI Hot Sheet
Price: $34.36 -0.41%

Rating Summary:
    15 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Piper Jaffray downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Neutral with a price target of $10.00 (from $22.00).

Analyst Dr. Charles Duncan maintains FY 2017 EPS estimate for a loss of $3.65, FY 2018 EPS estimate maintained at a loss of $3.77 and FY 2019 EPS estimate maintained at a loss $3.90.

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $13.82 Friday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst EPS View, Analyst PT Change, Downgrades

Related Entities

Piper Jaffray, The Children's Investment Fund (TCI), Charles Duncan